Clinical Trial: Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Detailed Summary:
Sponsor: Cephalon
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Teva Pharmaceutical Industries
Dates:
Date Received: March 11, 2005
Date Started: January 2005
Date Completion:
Last Updated: May 8, 2014
Last Verified: May 2014